CARTESIAN THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.68 USD | +0.46% |
|
+10.73% | -0.95% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
20.59
USD
Average target price
56.25
USD
Spread / Average Target
+173.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.95% | 366M | |
| -1.45% | 105B | |
| +3.89% | 97.5B | |
| +2.04% | 22.19B | |
| -15.93% | 21.33B | |
| -8.35% | 18.68B | |
| -42.33% | 16.6B | |
| -20.46% | 14.52B | |
| +6.41% | 14.09B | |
| +21.96% | 10.99B |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Selecta Biosciences : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform
